| Literature DB >> 28943983 |
Rana Abu Farha1, Akram Saleh2, Salah Aburuz3.
Abstract
BACKGROUND: Hypertension is a major cause of cardiovascular diseases with a high prevalence in Jordan. No previous studies have been carried out to determine the effect of the presence of drug-related problems (DRPs) on the health-related quality of life (HRQOL) among hypertensive patients.Entities:
Keywords: Cross-Sectional Studies; Hypertension; Jordan; Medication Adherence; Medication Errors; Patient Medication Knowledge; Quality of Life; Regression Analysis; Risk Factors
Year: 2017 PMID: 28943983 PMCID: PMC5597811 DOI: 10.18549/PharmPract.2017.03.995
Source DB: PubMed Journal: Pharm Pract (Granada) ISSN: 1885-642X
Demographic and clinical characteristics of study sample (n=200)
| Age, years. mean (SD) | 59.7 (10.2) |
| Male, n (%) | 79 (39.5%) |
| Marital status, n (%) | |
| Single | 2 (1%) |
| Married | 163(81.5%) |
| Others | 35 (17.5%) |
| Education, n(%) | |
| Not educated | 27 (13.5%) |
| Primary | 89 (44.5%) |
| Secondary | 12 (6%) |
| High School | 22 (11%) |
| Control of hypertension, n (%) | |
| Controlled | 103 (51.5%) |
| Uncontrolled | 97 (48.5%) |
| Duration of hypertension, years. mean (SD) | 8.4 (6.4) |
Percentages and examples of the various type of the identified DRPs
| DRPs categories | Examples |
|---|---|
| Indication drug related problems (12%) | |
| Patient has osteoporosis and she receives only alendronate, she needs additional therapy to treat osteoporosis so add vitamin D and CaCO3 | |
| Patient needs to start aspirin as secondary prophylaxis for coronary artery disease. | |
| Efficacy drug related problems (18%) | |
| It is more effective to use fibrate (gemfibrozil) instead of statin, since patient has hypertriglyceridemia [LDL= 59 mg/dl while TG = 214 mg/dl] | |
| It is more effective to use angiotensin converting enzyme inhibitor to treat hypertension in patient with diabetes than using atenolol | |
| The standard dose of gemfibrozil that should be used in patient with dyslipidemia should be 600 mg 1*2 not 600 mg 1*1 | |
| Safety drug related problems (11%) | |
| The dose of simvastatin that should be used in patient using fibrate should not exceed 10 mg 1*1 so reduce the dose of simvastatin from 20 mg to 10 mg 1*1 | |
| The maximum recommended dose of atenolol that can be used in hypertension should not exceed 100 mg /day and the patient receives 150mg /day, so reduce the dose of atenolol | |
| In a patient with CrCl 15-35 ml/min the maximum dose of atenolol that can be used should be 50 mg daily not 100 mg daily so reduce the dose. | |
| Enalapril causes cough to the patient, so change to angiotensin receptor antagonist like candesartan | |
| Inappropriate adherence to medications (11%) | |
| Patient needs education to understand his medication | |
| Patient needs education to understand non-pharmacological therapy | |
| Inappropriate knowledge about medications (24%) | |
| Patients does not adhere to medication | |
| Patient needs education to adhere to self-care activities (reduce salt intake, make exercise). | |
| Miscellaneous drug related problems (24%) | |
| Lipid profile needs monitoring | |
RAND-12 physical and Mental Health Composite scores among the study hypertensive patients (n= 200)
| Mental health composite (MHC) | Physical health composite (PHC) | |
|---|---|---|
| Mean | 60.5 | 58.3 |
| SD | 22.9 | 29.9 |
| Median | 66.7 | 70.8 |
| IQR | 47.7-76.7 | 29.2-87.5 |
| Actual DRPs | r= -0.278, p-value <0.05 | r= -0.375, p-value <0.05 |
SD: standard deviation; IQR: interquartile range, r: Pearson correlation coefficient
Simple linear regression analysis for actual DRPs affecting MHC of the RAND-12 quality of life
| Actual DRPs category | Dependent variable: MHC | ||||
|---|---|---|---|---|---|
| B Estimate | SE | Beta | R2 (%) | p-value[ | |
| Indication drug related problems [1: no, 2: yes] | -0.632 | 3.245 | -0.014 | 0.00% | 0.846 |
| Efficacy drug related problems [1: no, 2: yes] | -0.629 | 3.326 | -0.013 | 0.00% | 0.850 |
| Safety drug related problems [1: no, 2: yes] | -8.873 | 3.207 | -0.193 | 3.70% | 0.006 |
| Inappropriate adherence to medications [1: adherent, 2: non- adherent] | -11.305 | 3.182 | -0.245 | 6.00% | 0.000 |
| Inappropriate adherence to non-pharmacological therapy [1: adherent, 2: non-adherent] | -12.83 | 3.914 | -0.227 | 5.10% | 0.001 |
| Inappropriate knowledge about medications [1: know, 2: didn’t know] | -4.986 | 3.231 | -0.109 | 1.20% | 0.124 |
| Inappropriate knowledge about non-pharmacological therapy [1: know, 2: didn’t know] | -7.209 | 4.239 | -0.120 | 1.40% | 0.091 |
| Miscellaneous drug related problems [1: no, 2: yes] | -4.315 | 3.786 | -0.081 | 0.70% | 0.256 |
Simple linear regression analysis
Significant at 0.05 level.
MHC: Mental Health Composite
Multiple linear regression analysis of the actual DRPs affecting MHC of the RAND-12 quality of life
| Variables | Dependent variable: MHC | ||||
|---|---|---|---|---|---|
| B estimate | SE | Beta | R2 (%) | p-value[ | |
| Indication drug related problems [1: yes, 2: no] | 0.213 | 3.256 | 0.005 | 0.0% | 0.948 |
| Efficacy drug related problems [1: yes, 2: no] | 0.158 | 3.177 | 0.003 | 0.0% | 0.96 |
| Safety drug related problems [1: yes, 2: no] | -6.097 | 3.19 | -0.133 | 1.8% | 0.057 |
| Inappropriate adherence to medications [1: adherent, 2: non- adherent] | -9.626 | 3.268 | -0.208 | 4.3% | 0.004 |
| Inappropriate adherence to non-pharmacological therapy [1: adherent, 2: non-adherent] | -10.793 | 3.922 | -0.191 | 3.6% | 0.006 |
| Inappropriate knowledge about medications [1: know, 2: didn’t know] | -1.988 | 3.318 | -0.043 | 0.2% | 0.55 |
| Inappropriate knowledge about non-pharmacological therapy [1: know, 2: didn’t know] | -1.506 | 4.355 | -0.025 | 0.1% | 0.73 |
| Miscellaneous drug related problems [1: yes, 2: no] | -5.546 | 3.95 | -0.104 | 1.1% | 0.162 |
| Model | R=0.369; R2=13.6%, adjusted R2=10.0% | <0.05 | |||
Multiple linear regression analysis
Significant at 0.05 level,
MHC: Mental Health Composite
Simple linear regression analysis for actual DRPs affecting PHC of the RAND-12 quality of life
| Actual drug related problem category | Dependent variable: PHC | ||||
|---|---|---|---|---|---|
| B Estimate | SE | Beta | R2 % | p-value[ | |
| Indication drug related problems [1: no, 2: yes] | -4.864 | 4.223 | -0.082 | 0.70% | 0.251 |
| Efficacy drug related problems [1: no, 2: yes] | -7.493 | 4.31 | -0.123 | 1.50% | 0.084 |
| Safety drug related problems [1: no, 2: yes] | -6.906 | 4.239 | -0.115 | 1.30% | 0.105 |
| Inappropriate adherence to medications [1: adherent, 2: non- adherent] | -11.438 | 4.207 | -0.19 | 3.60% | 0.007 |
| Inappropriate adherence to non-pharmacological therapy [1: adherent, 2: non-adherent] | -19.321 | 5.065 | -0.262 | 6.80% | 0.000 |
| Inappropriate knowledge about medications [1: know, 2: didn’t know] | -18.204 | 4.042 | -0.305 | 9.30% | 0.000 |
| Inappropriate knowledge about non-pharmacological therapy [1: know, 2: didn’t know] | -13.113 | 5.497 | -0.167 | 2.80% | 0.018 |
| Miscellaneous drug related problems [1: no, 2: yes] | -11.556 | 4.892 | -0.166 | 2.70% | 0.019 |
Simple linear regression analysis
Significant at 0.05 level.
PHC: Physical Health Composite
Multiple linear regression analysis of the actual DRPs affecting PHC of the RAND-12 quality of life
| Variables | Dependent variable: PHC | ||||
|---|---|---|---|---|---|
| B estimate | SE | Beta | R2 (%) | p-value[ | |
| Indication drug related problems [1: yes, 2: no] | -2.078 | 4.087 | -0.035 | 0.12% | 0.612 |
| Efficacy drug related problems [1: yes, 2: no] | -5.359 | 3.988 | -0.088 | 0.77% | 0.181 |
| Safety drug related problems [1: yes, 2: no] | -3.916 | 4.004 | -0.065 | 0.42% | 0.329 |
| Inappropriate adherence to medications [1: adherent, 2: non- adherent] | -8.973 | 4.102 | -0.149 | 2.22% | 0.030 |
| Inappropriate adherence to non-pharmacological therapy [1: adherent, 2: non-adherent] | -16.652 | 4.923 | -0.226 | 5.11% | 0.001 |
| Inappropriate knowledge about medications [1: know, 2: didn’t know] | -13.707 | 4.165 | -0.23 | 5.29% | 0.001 |
| Inappropriate knowledge about non-pharmacological therapy [1: know, 2: didn’t know] | -1.16 | 5.466 | -0.015 | 0.02% | 0.832 |
| Miscellaneous drug related problems [1: yes, 2: no] | -8.717 | 4.958 | -0.125 | 1.56% | 0.08 |
| Model | R=0.449; R2=20.2%, adjusted R2=16.8% | <0.05 | |||
Multiple linear regression analysis
Significant at 0.05 level,
PHC: Physical Health Composite